Georges Rawadi, formerly of Cellectis SA, has joined Cardio3 BioSciences SA as vice president for business development. He will oversee the commercialisation of the company’s candidate cell therapy for heart disease. Dr Rawadi has held management positions at Galapagos NV, ProStrakan France and at Sanofi SA in addition to leading business development at Cellectis.
He holds a PhD in microbiology from the Pierre et Marie Curie University and a masters in management and strategy in the health industry from the ESSEC Business School in France.
Cardio3 BioSciences announced the appointment on 2 June 2014.
Copyright 2014 Evernow Publishing Ltd